The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantation in a Low Alpha-Fetoprotein Population.
Monique J C DevillersJohanna K F PluimersMaria C van HooffMichail DoukasWojciech Grzegorz PolakRobert A de ManMilan J SonneveldAndré BoonstraCaroline M den HoedPublished in: Cancers (2023)
The dual model of PIVKA-II ≤ 90 mAU/mL with either AFP ≤ 8 ng/mL or with patients within the Milan criteria identifies patient groups which can be exempted from HCC surveillance after LT in a low AFP population. PIVKA-II may be a better predictor for explant microvascular invasion than AFP and could play a role in future models identifying LT candidates with the highest risk for HCC recurrence.